Singapore markets closed
  • Straits Times Index

    3,142.45
    +12.68 (+0.41%)
     
  • S&P 500

    4,701.21
    +14.46 (+0.31%)
     
  • Dow

    35,754.75
    +35.32 (+0.10%)
     
  • Nasdaq

    15,786.99
    +100.07 (+0.64%)
     
  • BTC-USD

    49,386.22
    +83.46 (+0.17%)
     
  • CMC Crypto 200

    1,290.04
    -15.08 (-1.16%)
     
  • FTSE 100

    7,332.31
    -4.74 (-0.06%)
     
  • Gold

    1,783.80
    -1.70 (-0.10%)
     
  • Crude Oil

    72.14
    -0.22 (-0.30%)
     
  • 10-Yr Bond

    1.5090
    0.0000 (0.00%)
     
  • Nikkei

    28,725.47
    -135.15 (-0.47%)
     
  • Hang Seng

    24,254.86
    +257.99 (+1.08%)
     
  • FTSE Bursa Malaysia

    1,501.79
    +7.76 (+0.52%)
     
  • Jakarta Composite Index

    6,643.93
    +40.13 (+0.61%)
     
  • PSE Index

    7,234.92
    +87.62 (+1.23%)
     

Iridex to Report Third Quarter 2021 Financial Results on November 11, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MOUNTAIN VIEW, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 11, 2021. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 7496524. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com.

About Iridex
Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com.

Investor Relations Contact:
Leigh Salvo
(415) 937-5404
investors@iridex.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting